Amsbio has expanded its diverse range of recombinant and monoclonal antibodies to include over 10,000 new validated monospecific products in 15,000 formulations to support research in cancer, immunology, neuroscience, and signal transduction.

Every antibody in the new catalogue has been subject to rigorous validation technologies to confirm that they selectively recognize their intended targets across applications such as immunohistochemistry, western blot, flow cytometry and immunofluorescence. These recombinant and monoclonal antibodies also provide high sensitivity and minimal background signal, reducing the risk of false positives or non-specific binding.

Recombinant antibodies are a premium class of antibodies engineered through genetic manipulation techniques. They provide precision targeting, consistency and reproducibility, customization, scalability, and reduced immunogenicity, making them an invaluable tool for research, diagnostics, and therapeutics.  Monoclonal antibodies are identical antibodies derived from a single clone of B cells, meaning they all recognize the same specific epitope on an antigen. They are used to target specific antigens in diagnosis, treatment, and research into various diseases including cancer and autoimmune disorders

Benefiting from a completely controlled production process, the batch-to-batch reproducibility of these monospecific antibodies is exceptional, which is vital for longer term experiments. All these antibodies are developed and tested across hundreds of tumour types and normal tissues to ensure accurate epitope mapping and binding affinity.

For further information on these validated monospecific recombinant and monoclonal antibodies please visit https://www.amsbio.com/catalogsearch/result/?q=neobiotech or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected].

Amsbio, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research, and cell and gene therapy across Europe, North America, and wider international markets. With in depth expertise in advanced cell culture, 3D cell models, and cryopreservation, Amsbio is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development, and disease modelling, through to stem cell and organoid-based research. Key solutions include the integrated stem call platform combining StemFit™ media, iMatrix™ recombinant laminins, and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services including viral delivery. Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, Amsbio is internationally recognized for delivering high-quality, application-ready products and services. Amsbio has a consistent record of close scientific collaboration with partners in academic, biotech, and pharmaceutical markets to translate innovation from bench to bedside.